TLSA Tiziana Life Sciences |
$1.05
|
+15.9%
 |
intranasal foralumab
Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
|
Phase 2
|
10/16/2026 - Dose Update
Tiziana Life Sciences, Ltd. announced that the last patient has begun dosing in its Phase 2 randomiz…
Full Summary
|
TLSA Tiziana Life Sciences |
$1.05
|
+15.9%
|
intranasal foralumab
Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
|
Target date: Q1 2027
|
10/16/2026 - Top-line data
Tiziana Life Sciences, Ltd. announced that Topline data are anticipated to be announced in Q1 2027.
Full Summary
|
REGN Regeneron Pharmaceuticals |
$790.74
-0.7% |
+0.8%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
|
10/16/2026 - Positive Opinion
Regeneron Pharmaceuticals, Inc announced that the European Medicines Agency’s (EMA) Committee for M…
Full Summary
|
SNY Sanofi |
$40.61
+0.8% |
-4.4%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
|
10/16/2026 - Positive Opinion
Regeneron Pharmaceuticals, Inc announced that the European Medicines Agency’s (EMA) Committee for M…
Full Summary
|
TNGX Tango Therapeutics |
$22.04
-2.9% |
+1.3%
 |
vopimetostat
patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC).
|
Phase 1/2
|
10/16/2026 - Updated data
Tango Therapeutics, Inc. announced that the Company will present updated data from a Phase 1/2 stu…
Full Summary
|
OGN Organon & Co. |
$13.76
0.0% |
+0.5%
 |
MIUDELLA
Hormone-Free Intrauterine Device
|
Phase 3
|
10/16/2026 - presented results
Organon announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 st…
Full Summary
|
IONS Ionis Pharmaceuticals |
$42.94
-2.7% |
-3.4%
 |
Olezarsen (Formerly IONIS-APOCIII-L)
Severe hypertriglyceridemia
|
|
10/16/2026 - Positive Opinion
Ionis Pharmaceuticals, Inc announced that the Committee for Medicinal Products for Human Use (CHMP…
Full Summary
|
OMER Omeros |
$16.20
-13.8% |
-9.3%
 |
Narsoplimab
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
|
|
10/16/2026 - Negative opinion
Omeros Corporation announced that the European Medicines Agency’s CHMP issued a negative opinion on…
Full Summary
|
ASND Ascendis Pharma A/S |
$225.25
-0.6% |
-4.8%
 |
TransCon CNP
In Children with Achondroplasia
|
|
10/16/2026 - Positive Opinion
Ascendis Pharma A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of th…
Full Summary
|
INSM Insmed |
$96.27
-3.0% |
-19.8%
 |
Treprostinil Palmitil Inhalation Powder (TPIP)
Pulmonary arterial hypertension (PAH)
|
|
10/15/2026 - Provided Update
Insmed Incorporated a people-first global biopharmaceutical company striving to deliver first- and …
Full Summary
|
AQST Aquestive Therapeutics |
$3.78
-6.9% |
-18.0%
 |
Anaphylm
For epinephrine prodrug candidate product
|
NDA
|
10/15/2026 - NDA Resubmission
Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowle…
Full Summary
|
AQST Aquestive Therapeutics |
$3.78
-6.9% |
-18.0%
|
Anaphylm
For epinephrine prodrug candidate product
|
NDA
Target date: March 16, 2027
|
10/15/2026 - PDUFA Date
Aquestive Therapeutics, Inc. announced that the Prescription Drug User Fee Act (PDUFA) goal action…
Full Summary
|
AQST Aquestive Therapeutics |
$3.78
-6.9% |
-18.0%
|
Anaphylm
For epinephrine prodrug candidate product
|
Target date: Q4 2026
|
10/15/2026 - Provided Update
Aquestive Therapeutics, Inc. announced that the Ex-U.S. strategy remains on track with Canadian N…
Full Summary
|
MCRB Seres Therapeutics |
$2.46
-2.8% |
-38.5%
 |
SER-428
to Reduce Risk of Bloodstream Infections in Critically Ill Patients
|
|
10/15/2026 - Preclinical Data
Seres Therapeutics, Inc. announced that preclinical data supporting the development of SER-428, an i…
Full Summary
|
CLRB Cellectar Biosciences |
$1.14
-4.2% |
-52.1%
 |
Iopofosine I-131
Pediatric Brain and Solid Tumors
|
|
10/15/2026 - Results
Cellectar Biosciences, announced that efficacy results from a subset of patients treated with iopof…
Full Summary
|
IMCR Immunocore |
$29.40
-0.3% |
-8.1%
 |
IMC-S118AI
patient with type 1 diabetes
|
Phase 1
|
10/15/2026 - Dose Update
Immunocore Holdings plc announced that the first patient with type 1 diabetes (T1D) has been dosed …
Full Summary
|
LEGN Legend Biotech |
$18.48
-6.7% |
+4.9%
 |
LB2501
for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.
|
IND
|
10/15/2026 - FDA Clearance
Legend Biotech Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared t…
Full Summary
|
TARA Protara Therapeutics |
$2.32
-3.3% |
-34.6%
 |
THRIVE-3
in Patients on Parenteral Support
|
Phase 2b
|
10/15/2026 - Enrollment Update
Protara Therapeutics, Inc. announced that it has completed enrollment of the Phase 2b, open-label do…
Full Summary
|
JSPR Jasper Therapeutics |
$0.48
-9.8% |
-22.3%
 |
vensobafusp alfa
IgA Nephropathy
|
Phase 2
|
10/15/2026 - Enrollment Update
- Jasper Therapeutics, announced that it has completed enrollment of the IgA nephropathy (IgAN) coho…
Full Summary
|
JSPR Jasper Therapeutics |
$0.48
-9.8% |
-22.3%
|
vensobafusp alfa
IgA Nephropathy
|
Target date: Q1 2027
|
10/15/2026 - Expansion
Jasper Therapeutics, announces expansion cohort in patients with FSGS, with first patients anticipat…
Full Summary
|
EPRX Eupraxia Pharmaceuticals |
$6.62
-2.2% |
-22.8%
 |
EP-104GI
For Treatment of Eosinophilic Esophagitis
|
|
10/15/2026 - Provided Update
Eupraxia Pharmaceuticals Inc announced that the ongoing RESOLVE study evaluating the safety and eff…
Full Summary
|
LLY Eli Lilly and Company |
$1,258.04
+0.5% |
+9.1%
 |
mirikizumab-mrkz
For Crohn's disease
|
|
10/15/2026 - New Data
New data analyses from Eli Lilly show patients with moderately to severely active ulcerative coliti…
Full Summary
|
EDSA Edesa Biotech |
$2.57
-3.7% |
-37.9%
 |
EB06
Moderate-To-Severe Nonsegmental Vitiligo
|
|
10/15/2026 - FDA Clearance
Edesa Biotech, Inc. reported that the U.S. Food and Drug Administration (FDA) has cleared the compa…
Full Summary
|
EDSA Edesa Biotech |
$2.57
-3.7% |
-37.9%
|
EB06
Moderate-To-Severe Nonsegmental Vitiligo
|
Target date: Q4 2027
|
10/15/2026 - Top-line data
Edesa anticipates that topline data will be available fourth quarter 2027.
Full Summary
|
RVMD Revolution Medicines |
$177.96
-6.0% |
-6.8%
 |
daraxonrasib
For previously treated metastatic PDAC in patients with KRAS G12 mutations.
|
|
10/15/2026 - Positive Opinion
Revolution Medicines, announced that the European Medicines Agency’s (EMA) Committee for Medicinal …
Full Summary
|
VOGX Vogenx |
$14.53
-9.5% |
-55.3%
 |
VGX-001-013
for Post-Bariatric Hypoglycemia
|
|
10/15/2026 - Initiation
Vogenx, Inc. announced the initiation of EMERGE (VGX-001-013), its Phase 2b clinical trial evaluatin…
Full Summary
|
CBIO Crescent Biopharma |
$11.84
-5.1% |
-29.9%
 |
CR-001
Treatment of Advanced Solid Tumors
|
|
10/15/2026 - Enrollment Update
Crescent Biopharma, Inc. announced clinical pipeline momentum, including enrolling patients in coh…
Full Summary
|
MGNX MacroGenics |
$3.25
-3.6% |
-21.5%
 |
MGC030
In Patients With Advanced Solid Tumors
|
Phase 1
|
10/15/2026 - Dose Update
MacroGenics, Inc announced that the first patient has been dosed in the Phase 1 study of MGC030, a …
Full Summary
|
IRD Opus Genetics |
$3.84
-5.2% |
-25.9%
 |
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
|
10/15/2026 - Provided Update
Opus Genetics, Inc. presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy prog…
Full Summary
|
PHAR Pharming Group |
$9.37
-2.8% |
-11.2%
 |
Leniolisib
Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
|
Phase 2
|
10/14/2026 - Data Presentation
Pharming presented positive topline data from its Phase II trial of leniolisib in genetically ident…
Full Summary
|
QNRX Quoin Pharmaceuticals |
$3.90
-3.2% |
-44.8%
 |
QRX003
Nethertons Syndrome
|
Orphan Drug
|
10/14/2026 - Designation Grant
Quoin Pharmaceuticals Ltd. announces that its lead product candidate QRX003 has been granted Orphan…
Full Summary
|
OCGN Ocugen |
$0.78
-4.1% |
-26.4%
 |
OCU400 (AAV5-hNR2E3)
Retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
|
|
10/14/2026 - Provided Update
Ocugen, Inc. announced the execution of a licensing agreement with Roots Pharmaceutical, and its str…
Full Summary
|
PBLS Parabilis Medicines |
$22.75
-9.7% |
-45.5%
 |
Zolucatetide
key driver of a range of cancers and tumor types.
|
Phase 1/2
|
10/14/2026 - Provided Update
Parabilis Medicines announced the initiation of a dose-ranging clinical cohort evaluating zolucate…
Full Summary
|
TRDA Entrada Therapeutics |
$4.37
-8.6% |
-35.3%
 |
ELEVATE-44-201
For Duchenne Muscular Dystrophy
|
|
10/14/2026 - Provided Update
Entrada Therapeutics, Inc. announced that an independent Data Monitoring Committee (DMC), per study…
Full Summary
|
TRDA Entrada Therapeutics |
$4.37
-8.6% |
-35.3%
|
ELEVATE-44-201
For Duchenne Muscular Dystrophy
|
Target date: Q1 2027
|
10/14/2026 - Enrollment Update
Entrada Therapeutics, Inc. announced that the Cohort 2 enrollment complete with data expected in Q1…
Full Summary
|
TRDA Entrada Therapeutics |
$4.37
-8.6% |
-35.3%
|
ELEVATE-44-201
For Duchenne Muscular Dystrophy
|
Target date: LATE 2026
|
10/14/2026 - Data
Entrada Therapeutics, Inc. announced that the Company to receive ELEVATE-44-201 data from Cohort 1 …
Full Summary
|
ZLAB Zai Lab |
$23.19
-1.4% |
-9.8%
 |
ZL-1503
For the Treatment of Atopic Dermatitis
|
|
10/14/2026 - Data
Zai Lab Limited announced that data from the first clinical trial evaluating ZL-1503, the company’s…
Full Summary
|
ARWR Arrowhead Pharmaceuticals |
$55.90
-4.4% |
-15.9%
 |
ARO-MAPT
Treatment of Alzheimer's Disease and Other Tauopathies
|
Phase 1/2a
|
10/14/2026 - Interim Results
Arrowhead Pharmaceuticals, Inc. announced interim results from an ongoing Phase 1/2a study of ARO-MA…
Full Summary
|
BIVI BioVie |
$1.20
+6.2% |
-25.5%
 |
Bezisterim
For Parkinson's Disease Patients
|
|
10/14/2026 - Abstract
BioVie Inc. announced that two abstracts detailing results from the Company’s ADDRESS-LC Phase 2 tri…
Full Summary
|
ATRA Atara Biotherapeutics |
$9.18
-4.9% |
-5.3%
 |
Tabelecleucel (tab-cel)
Post-Transplant Lymphoproliferative Disease (PTLD)
|
BLA
|
10/14/2026 - FDA Accepted
Atara Biotherapeutics, Inc. announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), h…
Full Summary
|
SRPT Sarepta Therapeutics |
$17.10
-3.9% |
-15.0%
 |
SRP-1003
treatment of myotonic dystrophy type 1 (DM1)
|
|
10/14/2026 - Preclinical Data
Sarepta Therapeutics, Inc today presented new preclinical data at the 22nd Annual Meeting of the O…
Full Summary
|
ONCY Oncolytics Biotech |
$0.50
-9.0% |
-35.3%
 |
atezolizumab (Tecentriq)
Early-stage breast cancer
|
Phase 1/2
|
10/14/2026 - Provided Update
Oncolytics Biotech® Inc announced an update regarding the status of its GOBLET Phase 1/2 study, inc…
Full Summary
|
BLTE Belite Bio |
$142.78
-6.4% |
-16.5%
 |
Tinlarebant
In Stargardt Disease
|
|
10/14/2026 - Authorization
Belite Bio, Inc announced Marketing Authorization Application (MAA) submissions to the regulatory a…
Full Summary
|
RZLT Rezolute |
$3.58
-8.2% |
-6.8%
 |
Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism
|
Phase 3
|
10/14/2026 - open-label
Rezolute, Inc. announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now …
Full Summary
|
RZLT Rezolute |
$3.58
-8.2% |
-6.8%
|
Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism
|
Target date: H1 2026
|
10/14/2026 - Top-line results
Rezolute, Inc. announced that the Topline results expected mid-December 2026
Full Summary
|
ESLA Estrella Immunopharma |
$0.43
-19.7% |
-18.7%
 |
EB103
ARTEMIS® T-Cell Therapy
|
|
10/14/2026 - Provided Update
Estrella Immunopharma, Inc announced the activation of a fifth clinical site for its ongoing STARLI…
Full Summary
|
VNDA Vanda Pharmaceuticals |
$4.03
-5.0% |
-21.4%
 |
VQW-765
treatment of acute anxiety in adults with social anxiety disorder
|
|
10/14/2026 - Provided Update
Vanda Pharmaceuticals Inc provided an update on its clinical development program for VQW-765, a nove…
Full Summary
|
BMEA Biomea Fusion |
$0.87
+3.9% |
-52.5%
 |
BMF-650
GLP-1 receptor agonist
|
|
10/13/2026 - Results
Biomea Fusion, Inc. announced that it will report results from its Phase I GLP-131 clinical study …
Full Summary
|
BNTX BioNTech |
$87.71
-2.8% |
-8.7%
 |
BNT113
HPV-positive tumors
|
Phase 2/3
|
10/13/2026 - Top-line results
BioNTech SE announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04…
Full Summary
|
MRNA Moderna |
$218.01
-7.8% |
+41.5%
 |
mRNA-4157/V940 (KEYTRUDA)
Provide an additive benefit and enhance T cell-mediated destruction of tumor cells.
|
|
10/13/2026 - Results
Merck announced that first-time results from three pivotal clinical trials will be presented during…
Full Summary
|
MRK Merck & Co., Inc. |
$146.01
+0.6% |
-0.4%
 |
mRNA-4157/V940 (KEYTRUDA)
Provide an additive benefit and enhance T cell-mediated destruction of tumor cells.
|
|
10/13/2026 - Results
Merck announced that first-time results from three pivotal clinical trials will be presented during…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$11.10
-3.2% |
-9.0%
 |
zelicapavir
For respiratory syncytial virus
|
|
10/13/2026 - Data
Enanta Pharmaceuticals, Inc announced that data for zelicapavir, its oral, once-daily, N-protein in…
Full Summary
|
UTHR United Therapeutics |
$533.12
-1.5% |
+7.8%
 |
ralinepag
For the Treatment of Pulmonary Arterial Hypertension
|
|
10/13/2026 - Oral presentation
United Therapeutics Corporation announced that two oral and five poster presentations will be presen…
Full Summary
|
ALKS Alkermes |
$41.22
+2.8% |
-5.0%
 |
LUMRYZ® (sodium oxybate)
treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
|
|
10/13/2026 - Oral presentation
Alkermes plc announced plans to present two oral presentations and six posters from its industry-le…
Full Summary
|
ENTX Entera Bio |
$2.68
-3.2% |
-9.5%
 |
EB613
Parathyroid hormone (1-34), or PTH for osteoporosis
|
|
10/13/2026 - Poster Presentation
Entera Bio Ltd. announced data from a Plenary Poster Presentation (abstract #7062) and a Late-break…
Full Summary
|
BEAM Beam Therapeutics |
$23.47
-5.1% |
-5.9%
 |
BEAM-301
To Correct a Glycogen Storage Disease Type I Deficiency Disease
|
Phase 1/2
|
10/13/2026 - Initial Data
Beam Therapeutics Inc. announced that the company will present initial data from the ongoing Phase…
Full Summary
|
PHIO Phio Pharmaceuticals |
$0.87
-5.9% |
-15.4%
 |
PH-762 (INTASYL)
Murine colorectal cancer
|
|
10/13/2026 - Provided Update
Phio Pharmaceuticals Corp. announced the successful release of its first commercial-scale cGMP batch…
Full Summary
|
PHIO Phio Pharmaceuticals |
$0.87
-5.9% |
-15.4%
|
PH-762 (INTASYL)
Murine colorectal cancer
|
Phase 2b
Target date: Q1 2027
|
10/13/2026 - Initiation
Phio Pharmaceuticals Corp announced the Planned Phase 2b Clinical Trial Initiation in First Quarter …
Full Summary
|
PRLD Prelude Therapeutics |
$3.26
-1.8% |
-33.1%
 |
PRT13722
Oral KAT6A Selective Degrader
|
|
10/13/2026 - Provided Update
Prelude Therapeutics Incorporated announced a clinical trial collaboration and supply agreement wit…
Full Summary
|
PRLD Prelude Therapeutics |
$3.26
-1.8% |
-33.1%
|
PRT13722
Oral KAT6A Selective Degrader
|
Target date: Q4 2026
|
10/13/2026 - Enrollment Update
Prelude Therapeutics Incorporated announced that its on track to initiate enrollment in the fourth…
Full Summary
|
KURA Kura Oncology |
$9.08
-6.4% |
-22.6%
 |
KO-7246
For Diabetes
|
|
10/13/2026 - Provided Update
Caspian Therapeutics, Inc plan to outline the development strategy for KO-7246, Caspian’s selective,…
Full Summary
|
TRVI Trevi Therapeutics |
$11.88
-1.9% |
-20.5%
 |
nalbuphine ER
chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
|
Phase 2b
|
10/13/2026 - Provided Update
Trevi Therapeutics, announced that results from the Phase 2b CORAL trial were accepted as an oral …
Full Summary
|
STTK Shattuck Labs |
$5.42
-2.0% |
-9.8%
 |
SL-846
treatment of patients with inflammatory and immune-mediated diseases
|
|
10/13/2026 - Poster Presentation
Shattuck Labs, Inc announced two upcoming poster presentations at United European Gastroenterology …
Full Summary
|
LIFE Ethos Technologies Inc. Class A Common Stock |
$37.52
-3.2% |
+4.2%
 |
ATYR0101
For the treatment of interstitial lung disease
|
|
10/13/2026 - Publication
aTyr Pharma, Inc. announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in th…
Full Summary
|
SABS SAB Biotherapeutics |
$2.53
-2.3% |
-27.9%
 |
SAB-142
Anti-thymocyte hpAB therapeutic
|
Fast Track
|
10/13/2026 - Designation Grant
SAB Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fas…
Full Summary
|
RYTM Rhythm Pharmaceuticals |
$86.17
-2.0% |
-11.8%
 |
IMCIVREE (setmelanotide)
Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
|
|
10/13/2026 - Provided Update
Rhythm Pharmaceuticals, Inc. announced the commercial launch of IMCIVREE® (setmelanotide) in Japan…
Full Summary
|
AGMB AgomAb Therapeutics |
$8.28
-0.6% |
-32.0%
 |
Ontunisertib
Fibrostenosing Crohn’s Disease
|
Phase 2b
|
10/13/2026 - Dose Update
Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's gl…
Full Summary
|
ABBV AbbVie |
$285.32
+0.7% |
+8.1%
 |
Risankizumab-rzaa (SKYRIZI)
Moderate to Severe Crohn's Disease
|
Phase 3
|
10/13/2026 - Findings Update
AbbVie announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction tr…
Full Summary
|
TFX Teleflex |
$130.41
+1.7% |
+4.8%
 |
BIOMAG™-LL
for the treatment of de novo coronary lesions up to 38 mm
|
|
10/12/2026 - Enrollment Update
Teleflex Incorporated announced the successful completion of patient enrollment in the BIOMAG™-LL C…
Full Summary
|
BMY Bristol Myers Squibb |
$59.69
-1.4% |
-5.1%
 |
admilparant
in adults with idiopathic pulmonary fibrosis (IPF).
|
Phase 3
|
10/12/2026 - Top-line results
Bristol Myers Squibb announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating…
Full Summary
|
ANIP ANI Pharmaceuticals |
$72.29
+0.0% |
-5.1%
 |
SYNCHRONICITY
in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
|
|
10/12/2026 - Data
ANI Pharmaceuticals, Inc. announced that both 6-month and 24-month data from SYNCHRONICITY, its Ph…
Full Summary
|
ZBIO Zenas BioPharma |
$24.84
-2.2% |
-21.1%
 |
Obexelimab
Immunoglobulin G4-Related Disease (IgG4-RD)
|
|
10/12/2026 - Data
Zenas BioPharma, Inc. announced new obexelimab data in immunoglobulin G4-related disease (IgG4-RD) p…
Full Summary
|
TRAX First Tracks Biotherapeutics |
$34.46
-4.4% |
-10.7%
 |
ANB033
in Celiac Disease
|
Phase 1b
|
10/12/2026 - Top-line results
First Tracks Biotherapeutics, Inc. announced positive top-line results from Cohort 1 (gluten challe…
Full Summary
|
PHAT Phathom Pharmaceuticals |
$6.92
-7.7% |
-7.5%
 |
vonoprazan
For the Treatment of Heartburn Associated with Non-Erosive GERD
|
|
10/12/2026 - Efficacy Data
Phathom Pharmaceuticals, Inc. announced new cost-effectiveness data for VOQUEZNA® (vonoprazan), alo…
Full Summary
|
ODTX Odyssey Therapeutics |
$17.17
-2.3% |
-29.6%
 |
OD-001
in Ulcerative Colitis
|
|
10/12/2026 - Provided Update
Odyssey Therapeutics, Inc. announced that it will present the design of a randomized, double-blind …
Full Summary
|
STOK Stoke Therapeutics |
$24.17
-1.8% |
-15.0%
 |
STK-002
Autosomal Dominant Optic Atrophy (ADOA)
|
|
10/12/2026 - Data Presentation
Stoke Therapeutics, Inc. announced two presentations of data for STK-002 at the American Academy of…
Full Summary
|
MIRM Mirum Pharmaceuticals |
$80.14
-2.7% |
-12.7%
 |
Maralixibat
Alagille Syndrome
|
Phase 3
|
10/12/2026 - Top-line results
Mirum Pharmaceuticals, Inc announced topline results from the Phase 3 EXPAND study evaluating LIVMA…
Full Summary
|
PALI Palisade Bio |
$1.41
-8.4% |
-11.3%
 |
PALI-2108
For patients affected by UC.
|
|
10/12/2026 - Findings Update
Palisade Bio, Inc announced clinical and translational findings featured in five poster presentation…
Full Summary
|
COCH Envoy Medical |
$0.67
+3.6% |
-6.4%
 |
Acclaim
for Breakthrough Hearing Device
|
Modular Premarket Approval
|
10/12/2026 - Application Submitted
- Envoy Medical® announced the submission of the second module of its Modular Premarket Approval ("P…
Full Summary
|
COCH Envoy Medical |
$0.67
+3.6% |
-6.4%
|
Acclaim
for Breakthrough Hearing Device
|
Target date: Q2 2027
|
10/12/2026 - Provided Update
Envoy Medical® announced that the Advances Toward Targeted Completion of the Final Clinical Module …
Full Summary
|
REGN Regeneron Pharmaceuticals |
$790.74
-0.7% |
+0.8%
|
garetosmab-grts
in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
|
Phase 3
|
10/12/2026 - Results
Regeneron Pharmaceuticals, Inc announced positive 84-week results from the Phase 3 OPTIMA trial eva…
Full Summary
|
CYTK Cytokinetics |
$61.95
-3.1% |
-9.9%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
|
10/12/2026 - Additional data
Cytokinetics, Incorporated announced that additional data from ACACIA-HCM (Assessment Comparing Afi…
Full Summary
|
SNDX Syndax Pharmaceuticals |
$12.90
-5.5% |
-26.8%
 |
Axatilimab
Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2
|
10/12/2026 - Endpoint Missed
Syndax Pharmaceuticals announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmona…
Full Summary
|
JNJ Johnson & Johnson |
$255.54
+0.9% |
-5.3%
 |
Guselkumab
For Treatment Of Adults With Moderately To Severely Active Ulcerative Colitis
|
Phase 3
|
10/12/2026 - New Data
Johnson & Johnson announced new Phase 3 data showing consistent combined fistula remission outcome…
Full Summary
|
SVRA Savara |
$4.45
-6.1% |
-17.1%
 |
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
10/12/2026 - Oral presentation
Savara Inc. announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA…
Full Summary
|
ORGO Organogenesis |
$1.00
-9.9% |
-29.6%
 |
PuraPly®AM
for Hard-to-Heal Diabetic Foot Ulcers
|
|
10/12/2026 - Publication
Organogenesis Holdings Inc. announced the publication of previously released results from PREPARE1,…
Full Summary
|
MIRM Mirum Pharmaceuticals |
$80.14
-2.7% |
-12.7%
|
Maralixibat
Alagille Syndrome
|
Phase 3
|
10/11/2026 - Provided Update
Mirum Pharmaceuticals, Inc. announced that it will host an investor call on Monday, October 12, 202…
Full Summary
|
TRAX First Tracks Biotherapeutics |
$34.46
-4.4% |
-10.7%
|
ANB033
in Celiac Disease
|
|
10/11/2026 - Provided Update
First Tracks Biotherapeutics, Inc. will host an investor call and live webcast to review top-line da…
Full Summary
|
ABBV AbbVie |
$285.32
+0.7% |
+8.1%
|
SKYRIZI (risankizumab-rzaa) PsA
Active Psoriatic Arthritis
|
|
10/11/2026 - Presentation
AbbVie announced the presentation of 22 scientific abstracts from its market-leading inflammatory …
Full Summary
|
BBIO BridgeBio Pharma |
$66.39
-1.1% |
-0.3%
 |
Encaleret
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
|
|
10/11/2026 - Results
BridgeBio Pharma, Inc. today presented bone turnover results and patient-reported outcomes from the …
Full Summary
|
MRK Merck & Co., Inc. |
$146.01
+0.6% |
-0.4%
|
BRUNELLO
For Diabetic Macular Edema
|
Phase 2b/3
|
10/10/2026 - Presentation
Merck announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO tri…
Full Summary
|
LBRX LB Pharmaceuticals |
$36.74
+0.1% |
-13.5%
 |
LB-102
In Patients With Bipolar Depression
|
|
10/10/2026 - Presentation
LB Pharmaceuticals Inc announced the presentation of four posters at the 39th European College of N…
Full Summary
|
ALMS Alumis |
$6.12
-3.0% |
-21.2%
 |
envudeucitinib
in Moderate-to-Severe Plaque Psoriasis
|
Phase 3
|
10/9/2026 - New Data
Alumis Inc. announced new envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWA…
Full Summary
|
LLY Eli Lilly and Company |
$1,258.04
+0.5% |
+9.1%
|
Taltz
adults with psoriasis and obesity or overweight
|
Phase 3b
|
10/9/2026 - Data
Eli Lilly and Company announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial…
Full Summary
|
GKOS Glaukos |
$164.46
-0.7% |
+0.7%
 |
iDose TR
Glaucoma
|
Phase 4
|
10/9/2026 - Top-line results
Glaukos Corporation announced positive topline results from the Phase 4 prospective, randomized, co…
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$41.44
+0.8% |
+6.0%
 |
WELTRUZA
Adults with Schizophrenia
|
|
10/9/2026 - FDA approved
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.…
Full Summary
|
PRTC PureTech Health |
$17.42
|
|
SPT-320
to treat generalized anxiety disorder
|
|
10/9/2026 - Presentation
Seaport Therapeutics, Inc announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320…
Full Summary
|
JNJ Johnson & Johnson |
$255.54
+0.9% |
-5.3%
|
Icotrokinra
For adults and adolescents with plaque psoriasis
|
Phase 3
|
10/9/2026 - Results
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICO…
Full Summary
|
ARQT Arcutis Biotherapeutics |
$28.82
-1.0% |
+13.7%
 |
ZORYVE™ (roflumilast)
Inhibitor of phosphodiesterase-4 (PDE4)
|
|
10/9/2026 - Data Presentation
Arcutis Biotherapeutics, Inc announced data presented across its ZORYVE® (roflumilast) portfolio a…
Full Summary
|
MIST Milestone Pharmaceuticals |
$0.71
-11.0% |
-22.8%
 |
ReVeRA-301
treatment of atrial fibrillation with rapid ventricular rate
|
|
10/9/2026 - Enrollment Update
Milestone® Pharmaceuticals Inc announced that the first European patient has been enrolled in ReVe…
Full Summary
|
